Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy

Blood

Volumn 126, Issue 22, 2015, Pages 2475-2478

  Dhodapkar, Madhav V ^a   Sexton, Rachael ^b,c   Das, Rituparna ^a   Dhodapkar, Kavita M ^a   Zhang, Lin ^a   Sundaram, Ranjini ^a   Soni, Sonal ^a   Crowley, John J ^b,c   Orlowski, Robert Z ^d   Barlogie, Bart ^e  

^a YALE UNIVERSITY   (United States)

^b SWOG STATISTICAL CENTER   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; TRANSCRIPTION FACTOR SOX2; CD274 PROTEIN, HUMAN; SOX2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SOX; TUMOR ANTIGEN;

ANTIGEN SPECIFICITY; ARTICLE; CANCER GROWTH; CELL CYCLE CHECKPOINT; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); HUMAN; HUMORAL IMMUNITY; IMMUNITY; IMMUNOCOMPETENT CELL; LYMPHOCYTIC INFILTRATION; MONOCLONAL IMMUNOGLOBULINEMIA; MYELOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RISK ASSESSMENT; TUMOR MICROENVIRONMENT; B LYMPHOCYTE; CLINICAL TRIAL; FEMALE; IMMUNOLOGY; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; PATHOLOGY; STEM CELL; T LYMPHOCYTE;

ANTIGENS, CD274; ANTIGENS, NEOPLASM; B-LYMPHOCYTES; FEMALE; HUMANS; IMMUNITY, CELLULAR; MALE; MULTIPLE MYELOMA; PROSPECTIVE STUDIES; SOXB1 TRANSCRIPTION FACTORS; STEM CELLS; T-LYMPHOCYTES;

EID: 84948845585     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-03-632919     Document Type: Article

References (25)

1. Pardoll DM The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4): 252-264.
2. Vesely MD, Schreiber RD. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Ann N Y Acad Sci. 2013; 1284: 1-5.
3. Bindea G, Mlecnik B, Fridman WH, Pagès F, Galon J. Natural immunity to cancer in humans. Curr Opin Immunol. 2010; 22(2): 215-222.
4. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011; 364(11): 1046-1060.
5. Zhao S, Choi M, Heuck C, et al. Serial exome analysis of disease progression in premalignant gammopathies. Leukemia. 2014; 28(7): 1548-1552.
6. Dhodapkar MV, Krasovsky J, Olson K. T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. Proc Natl Acad Sci USA. 2002; 99(20): 13009-13013.
7. Dhodapkar MV, Krasovsky J, Osman K, Geller MD. Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J Exp Med. 2003; 198(11): 1753-1757.
8. Noonan K, Matsui W, Serafini P, et al. Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors. Cancer Res. 2005; 65(5): 2026-2034.
9. Spisek R, Kukreja A, Chen LC, et al. Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J Exp Med. 2007; 204(4): 831-840.
10. Blotta S, Tassone P, Prabhala RH, et al. Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance. Blood. 2009; 114(15): 3276-3284.
11. Liu K, Lin B, Zhao M, et al. The multiple roles for Sox2 in stem cell maintenance and tumorigenesis. Cell Signal. 2013; 25(5): 1264-1271.
12. Tanno T, Lim Y, Wang Q, et al. Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells. Blood. 2014; 123(5): 725-733.
13. Brennan SK, Wang Q, Tressler R, et al. Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms. PLoS One. 2010; 5(9): e12487.
14. Dhodapkar MV, Sexton R, Waheed S, et al. Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood. 2014; 123(1): 78-85.
15. Dhodapkar KM, Gettinger SN, Das R, Zebroski H, Dhodapkar MV. SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer. OncoImmunology. 2013; 2(7): e25205.
16. Das R, Verma R, Sznol M, et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol. 2015; 194(3): 950-959.
17. Cox DR Regression models and life-tables. J R Stat Soc Series B Stat Methodol. 1972; 34(2): 187-220.
18. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999; 18(6): 695-706.
19. Leblanc M, Crowley J. Survival trees by goodness of split. J Am Stat Assoc. 1993; 88(422): 457-467.
20. Schmitz M, Temme A, Senner V, et al. Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy. Br J Cancer. 2007; 96(8): 1293-1301.
21. Benson DM Jr, Bakan CE, Mishra A, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood. 2010; 116(13): 2286-2294.
22. Liu J, Hamrouni A, Wolowiec D, et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-gamma and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood. 2007; 110(1): 296-304.
23. Paiva B, Azpilikueta A, Puig N, et al. PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma. Leukemia. 2015; 29(10): 2110-2113.
24. Kearl TJ, Jing W, Gershan JA, Johnson BD. Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma. J Immunol. 2013; 190(11): 5620-5628.
25. Dhodapkar MV Immunity to stemness genes in human cancer. Curr Opin Immunol. 2010; 22(2): 245-250.